NCT04064827 - A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

November 30, 2026

Study Completion Date

March 31, 2027

Conditions

Chronic Kidney Disease (CKD)Secondary Hyperparathyroidism (SHPT)

Interventions

DRUG

Paricalcitol

Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser

Trial Locations (15)

Atrium Health Wake Forest Baptist Medical Center /ID# 266045, Winston-Salem

Arkansas Children's Hospital /ID# 225417, Little Rock

Stanford University School of Medicine - Redwood City /ID# 252150, Redwood City

Seattle Children's Hospital /ID# 162861, Seattle

Childrens National Medical Center /ID# 225991, Washington D.C.

Holtz Childrens Hospital, University of Miami /ID# 225636, Miami

Nicklaus Children's Hospital /ID# 210517, Miami

Emory University /ID# 140665, Atlanta

Augusta University Medical Center /ID# 252149, Augusta

Boston Children's Hospital /ID# 162863, Boston

Duplicate_Levine Children's Specialty Center- Charlotte /ID# 216057, Charlotte

Children's Hospital of Philadelphia - Main /ID# 213802, Philadelphia

University of Texas Southwestern Medical Center /ID# 210495, Dallas

University of Utah /ID# 140669, Salt Lake City

School of Medicine University of Puerto Rico-Medical Science Campus /ID# 140663, San Juan